Literature DB >> 7485291

Underlying disorders associated with severe early-onset preeclampsia.

G A Dekker1, J I de Vries, P M Doelitzsch, P C Huijgens, B M von Blomberg, C Jakobs, H P van Geijn.   

Abstract

OBJECTIVE: Our purpose was to determine whether patients with severe early-onset preeclampsia have hemostatic or metabolic abnormalities that are associated with a tendency to vascular thrombosis. STUDY
DESIGN: A total of 101 patients with a history of severe early-onset preeclampsia were tested at least 10 weeks post partum for the presence of hyperhomocysteinemia (methionine loading test), protein C, protein S, and antithrombin III deficiency, activated protein C resistance, lupus anticoagulant, and immunoglobulin G and/or M anticardiolipin antibodies.
RESULTS: Of the 101 patients, 39 (38.6%) had chronic hypertension. Of the 85 patients tested for coagulation disturbances, 21 (24.7%) had protein S deficiency. Of the 50 patients tested for activated protein C resistance, 8 (16.0%) were positive. Of the 79 patients tested for hyperhomocysteinemia, 14 (17.7%) had a positive methionine loading test. Finally, 95 patients were tested for anticardiolipin antibodies; 27 (29.4%) had detectable immunoglobulin G and/or M anticardiolipin antibodies.
CONCLUSION: Patients with a history of severe early-onset preeclampsia should be screened for protein S deficiency, activated protein C resistance, hyperhomocysteinemia, and anticardiolipin antibodies, since these results may have an impact on counseling for and pharmacologic management in future pregnancies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7485291     DOI: 10.1016/0002-9378(95)91324-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  39 in total

Review 1.  Pathophysiology and maternal biologic markers of preeclampsia.

Authors:  Jacques Massé; Yves Giguère; Abdelaziz Kharfi; Joël Girouard; Jean-Claude Forest
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

2.  Impact of folic acid intake during pregnancy on genomic imprinting of IGF2/H19 and 1-carbon metabolism.

Authors:  Aggeliki Tserga; Alexandra M Binder; Karin B Michels
Journal:  FASEB J       Date:  2017-08-04       Impact factor: 5.191

3.  My approach to performing a perinatal or neonatal autopsy.

Authors:  H C Wainwright
Journal:  J Clin Pathol       Date:  2006-07       Impact factor: 3.411

4.  Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia.

Authors:  S Sohda; T Arinami; H Hamada; N Yamada; H Hamaguchi; T Kubo
Journal:  J Med Genet       Date:  1997-06       Impact factor: 6.318

5.  Primary antiphospholipid nephropathy beginning during pregnancy.

Authors:  Evandro M Klumb; Maria Celia de Andrade; Nilson R Jesús; Carlos Campani; Carlos F Campos; Roger A Levy; Elisa Albuquerque; Vicente Cervantes
Journal:  Rheumatol Int       Date:  2006-09-21       Impact factor: 2.631

Review 6.  The genomic basis of cerebral palsy: a HuGE systematic literature review.

Authors:  M E O'Callaghan; A H MacLennan; E A Haan; G Dekker
Journal:  Hum Genet       Date:  2009-02-24       Impact factor: 4.132

Review 7.  Low-molecular-weight heparins during pregnancy.

Authors:  Ariel Many; Gideon Koren
Journal:  Can Fam Physician       Date:  2005-02       Impact factor: 3.275

8.  Natural coagulation inhibitors and active protein c resistance in preeclampsia.

Authors:  Cengiz Demir; Imdat Dilek
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

9.  Effects of hyperhomocysteinemia on arterial pressure and nitric oxide production in pregnant rats.

Authors:  Derrick L Chandler; Maria T Llinas; Jane F Reckelhoff; Babbette LaMarca; Joshua Speed; Joey P Granger
Journal:  Am J Hypertens       Date:  2009-07-23       Impact factor: 2.689

10.  Homocysteine as Predictive Marker for Pregnancy-Induced Hypertension-A Comparative Study of Homocysteine Levels in Normal Versus Patients of PIH and Its Complications.

Authors:  Laxmi Maru; Monica Verma; Neha Jinsiwale
Journal:  J Obstet Gynaecol India       Date:  2016-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.